Boya Bio-Pharmaceutical Group Co.Ltd(300294) independent director
Prior approval opinions on relevant matters of the 15th meeting of the seventh board of directors of the company
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the standards for the governance of listed companies, the guiding opinions on the establishment of independent director system in listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies, the Boya Bio-Pharmaceutical Group Co.Ltd(300294) independent director working system and other relevant laws According to the regulations and normative documents, as an independent director of Boya Bio-Pharmaceutical Group Co.Ltd(300294) (hereinafter referred to as “the company”), in a serious and responsible manner, based on an independent, prudent and objective position, the independent director has conducted a pre review on the relevant matters considered at the 15th meeting of the seventh board of directors of the company and expressed the following independent opinions:
1、 Prior approval opinions on the company’s reappointment of audit institutions in 2022
It is verified that Ernst & Young Huaming Certified Public Accountants (special general partnership) adheres to the independent audit standards in the audit of the company in 2021, reflects the rich experience and professional quality in the audit of listed companies, can meet the requirements of the company’s financial audit in 2022, and can audit the company’s financial status independently. In order to maintain the stability and continuity of the company’s audit work, the independent directors agreed to renew the appointment of Ernst & Young Huaming Certified Public Accountants (special general partnership) as the company’s audit institution in 2022, and hired it as the audit institution of the company’s internal control. They agreed to submit the matter of the company’s renewal of the audit institution in 2022 to the board of directors for deliberation.
2、 Prior approval opinions on the amount of daily related party transactions with related parties in 2022
After verification, the difference between the estimated daily related party transaction amount and the actual transaction amount of the company in 2021 is mainly due to the growth of the company’s business in 2021 and the synergy between the company’s business and China Resources pharmaceutical holding business. The company expects that the daily related party transaction in 2022 belongs to the needs of the company’s normal business scope, the amount is appropriate, and the pricing policy follows the principles of openness, fairness, impartiality and voluntariness, There is no situation that damages the interests of the company and all shareholders, especially minority shareholders. The independent directors agree to submit the difference between the estimated daily connected transaction amount and the actual transaction amount in 2021 and the estimated daily connected transaction amount with related parties in 2022 to the board of directors of the company for deliberation.
On March 22, 2022 (there is no text below, which is the signature page of Boya Bio-Pharmaceutical Group Co.Ltd(300294) independent directors’ prior approval opinions on relevant matters of the 15th meeting of the seventh board of directors of the company):
Zhang Weidong
Huang Huasheng
Zhao Li
